- Home
- AIRJ vs CERS Comparison
AIRJ vs CERS Comparison
Compare AIRJ & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJ
- CERS
- Stock Information
- Founded
- AIRJ 2018
- CERS 1991
- Country
- AIRJ United States
- CERS United States
- Employees
- AIRJ N/A
- CERS N/A
- Industry
- AIRJ
- CERS EDP Services
- Sector
- AIRJ
- CERS Technology
- Exchange
- AIRJ NYSE
- CERS Nasdaq
- Market Cap
- AIRJ 256.6M
- CERS 271.4M
- IPO Year
- AIRJ N/A
- CERS 1997
- Fundamental
- Price
- AIRJ $4.64
- CERS $1.47
- Analyst Decision
- AIRJ Strong Buy
- CERS Strong Buy
- Analyst Count
- AIRJ 1
- CERS 2
- Target Price
- AIRJ $12.00
- CERS $3.50
- AVG Volume (30 Days)
- AIRJ 297.1K
- CERS 1.1M
- Earning Date
- AIRJ 08-22-2025
- CERS 07-31-2025
- Dividend Yield
- AIRJ N/A
- CERS N/A
- EPS Growth
- AIRJ N/A
- CERS N/A
- EPS
- AIRJ 0.86
- CERS N/A
- Revenue
- AIRJ N/A
- CERS $185,144,000.00
- Revenue This Year
- AIRJ N/A
- CERS $20.97
- Revenue Next Year
- AIRJ N/A
- CERS $15.55
- P/E Ratio
- AIRJ $5.39
- CERS N/A
- Revenue Growth
- AIRJ N/A
- CERS 13.06
- 52 Week Low
- AIRJ $3.74
- CERS $1.12
- 52 Week High
- AIRJ $11.75
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- AIRJ 49.96
- CERS 55.09
- Support Level
- AIRJ $4.60
- CERS $1.45
- Resistance Level
- AIRJ $5.63
- CERS $1.56
- Average True Range (ATR)
- AIRJ 0.42
- CERS 0.08
- MACD
- AIRJ 0.02
- CERS 0.01
- Stochastic Oscillator
- AIRJ 32.88
- CERS 64.06
About AIRJ MONTANA TECHNOLOGIES CORP
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.